Advertisement

Topics

Latest "Safety and Efficacy Study of EGT0001442 in Subjects With Type 2 Diabetes Mellitus" News Stories

10:44 EDT 19th March 2019 | BioPortfolio

Here are the most relevant search results for "Safety and Efficacy Study of EGT0001442 in Subjects With Type 2 Diabetes Mellitus" found in our extensive news archives from over 250 global news sources.

More Information about Safety and Efficacy Study of EGT0001442 in Subjects With Type 2 Diabetes Mellitus on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Safety and Efficacy Study of EGT0001442 in Subjects With Type 2 Diabetes Mellitus for you to read. Along with our medical data and news we also list Safety and Efficacy Study of EGT0001442 in Subjects With Type 2 Diabetes Mellitus Clinical Trials, which are updated daily. BioPortfolio also has a large database of Safety and Efficacy Study of EGT0001442 in Subjects With Type 2 Diabetes Mellitus Companies for you to search.

Showing "Safety Efficacy Study EGT0001442 Subjects With Type Diabetes" News Articles 1–25 of 39,000+

Tuesday 19th March 2019

Camstent announces positive initial results for bacteria-phobic catheter

The study involved 10 Camstent coated catheters and 12 uncoated silicone catheters, which showed clear reduction in biofilm formation and biomineralisation on the Camstent polymer coated catheters compared The post Camstent announces positive initial results for bacteria-phobic catheter appeared first on Compelo Medical Devices - Latest industry news and analysis.


Rex Medical Completes Patient Enrollment for the REVEAL Peripheral Atherectomy U.S. Trial

Rex Medical, L.P., a medical device design and development company, today announced the successful completion of enrollment in the Revolution™ Peripheral Atherectomy System for Lower Extremity Peripheral Arterial Revascularization (REVEAL) IDE clinical trial. The REVEAL trial is a single arm, prospective study to evaluate the safety and effectiven...

Avocado Seed Extract Shows Promise As Anti-inflammatory Compound

NewsAn extract from the seeds of avocados exhibited anti-inflammatory properties in a laboratory study.Contributed Author:&nb


VisionCare, Inc. Announces Regulatory Approval of the CentraSight Treatment Program in Australia

The Telescope Implant for End-Stage Macular Degeneration is Approved and Available Around the World in Patients Who Meet Age Requirements and Who Have Not Had Cataract Surgery VisionCare, Inc. ("VisionCare”), a developer of advanced visual prosthetic devices for the treatment of age-related macular degeneration (AMD), today announced that the Au...

Aesthetics Biomedical Introduces Vivace 3D Precision – An Optimized, Layered, and Precise Approach to RF Microneedling Treatments

Aesthetics Biomedical Introduces Vivace 3D Precision – An Optimized, Layered, and Precise approach to RF Microneedling Treatments PHOENIX (PRWEB) March 19, 2019 Aesthetics Biomedical, Inc., the innovators behind Vivace RF Microneedling Experience and the use of radio frequency technology, in partnership with its physician network, is advancing the Vivace 3D Precision Treatment concept. A layer...

Agility in Rare Disease and Oncology Clinical Trials – Data Management, New Webinar Hosted by Xtalks

Modular and adaptive clinical trials are rapidly expanding the ability of researchers to modify clinical trials based on emerging data, i.e. to make better decisions based on positive clinical response. This is a flexible process which provides data on the smallest number of patients so that drug developers can pre-plan alternative paths for the trial during the design stage. TORONTO (PRWEB) March...

City of Lancaster Renews Automated Cannabis Facility Compliance Enforcement Program from Adherence Compliance

Adherence Compliance Inc., the leading RegTech SaaS compliance provider in the cannabis industry, today announced the renewal of its annual contract with the City of Lancaster, California for automated cannabis facility compliance enforcement and program management. The city’s program utilizes Adherence’s monthly program management, cannabis industry o...

Millendo Therapeutics Initiates Pivotal Phase 2b/3 Clinical Study of Livoletide for the Treatment of Prader-Willi Syndrome

Top-line Phase 2b results are expected in 1H 2020 and may support an NDA submission for livoletide Millendo Therapeutics, Inc. (Nasdaq: MLND), a clinical-stage biopharmaceutical company developing novel treatments for orphan endocrine dise

Endospan Secures CE Mark Approval for Branched Endovascular Repair of the Aortic Arch with Its NEXUS™ Aortic Arch Repair System

With regulatory approval in Europe of its innovative NEXUS™ Stent Graft System, Endospan intends to transform the treatment of life-threatening Aortic Arch Disease from a high-risk open surgery into a minimally invasive aortic arch repair for both aneurysms and dissections. Endospan, a pioneer in off-the-shelf, minimally invasive endovascular repair ...

Cybersecurity breach pay: CEOs get pay rises following an attack while shareholders lose out

A study into cybersecurity breach pay has found that in the aftermath of a cyberattack or other similar security breach,...Read More... The post Cybersecurity breach pay: CEOs get pay rises following an attack while shareholders lose out appeared first on Pharmaceutical Technology.

Contraception App Claims It’s 99 Percent Effective, But Questions About How To Even Test That Rate Remain Unanswered

The app gives users a window of about 11 to 13 days during which they should use a condom or another birth control method to prevent pregnancy. Although a new study shows that it can be effective if used correctly, that data assumes the people who don't respond aren't pregnant, which is an underlying obstacle to proving efficacy on apps like these. In other public health news: the microbiome, brok...

Apple Watch shows promise in heart study, but doctors sceptical

Study important for Apple's ambitions in healthcare

New Cognition® Corporation eBook Focuses on Risk Management

New eBook Details the Importance and Foundation of Risk Management Programs in Life Science Industries LEXINGTON, Mass. (PRWEB) March 19, 2019 Cognition® Corporation, a software company specializing in medical device compliance and commercialization, has just released a new ebook discussing foundational aspects of risk management in life sciences. Risk management is a vital part of the compl...

Nativis Announces Name Change To EMulate Therapeutics, Inc.

CRO Selected to Conduct Pivotal Clinical Studies for Newly Diagnosed GBM SEATTLE (PRWEB) March 19, 2019 Nativis, Inc., today announced the Company has changed its name to EMulate Therapeutics, Inc. The name change is effective immediately for the clinical stage, therapeutic device company, which is developing non-invasive treatments for cancers and other serious diseases. In making the announcem...

Nature Publishing Group Study Highlights Potential of Indee Labs Technology as an Alternative to Current Gene-Modified Cell Therapy Manufacturing

Microfluidic method could speed up life-saving chimeric antigen receptor T cell (CAR-T) treatments for advanced cancer patients and solve the scalability challenges Indee Labs announced the publication of a proof-of-concept study demonstrating the efficacy of its gene-modified cell therapy (GMCT) development and manufacturing technology in Nature’s

NeuroPointDX to Present Precision Medicine Approaches to Diagnosing and Treating Autism at National TACA Autism Conference

Company Will Present New Data from the 1,100 Patient Clinical Study, the Children’s Autism Metabolome Project (CAMP) NeuroPointDX, a business unit of Stemina Biomarker Discovery, today announced the company will present recent data from the Children’s Autism Metabolome Project (CAMP ), its large, comprehensive clinical study, supp...

Urovant Sciences Announces Positive Topline Results from Pivotal Phase 3 EMPOWUR Study of Vibegron in Patients with Overactive Bladder

Vibegron met both co-primary endpoints demonstrating highly significant reduction in daily urge urinary incontinence episodes and micturitions, compared to placebo (p<0.0001 and p<0.001, respectively) Vibegron met all seven key secondary endpoints, including a clinically meaningful reduction in daily urgency episodes versus ...

Clovis Oncology Announces Presentations at 2019 AACR Annual Meeting

Accepted abstracts highlight data from a phase 2 investigator-initiated trial of Rubraca® (rucaparib) in pancreatic cancer, clinical and nonclinical research of Rubraca in multiple solid tumor settings, and nonclinical research exploring lucitanib in multiple solid tumor models Clovis Oncology, Inc. (NASDAQ: CLVS) today announced that six abstracts ...

Standardized Morphine Infusions for Use in Children

This study investigated the feasibility and safety of quality assured, standardized concentrations of pediatric nurse/patient-controlled morphine infusions, supplied as pre-filled syringes. BMC Anesthesiology

Cardioversion of Obese Patients

What do we know about the efficacy and safety of conventional cardioversion methods in obese patients? Should alternative techniques be considered in this population? Journal of Cardiovascular Electrophysiology

Estimating National Rates of HIV Infection in the U.S.

How have the rates of HIV diagnosis and prevalence changed in recent years? A new study uses surveillance data to estimate the national trends among different groups. AIDS

Needle-free ‘dominates’ injectable drug delivery market

Disposable injectors are the most commonly available type of injectors since they are user friendly and do not require special skills for administration... The post Needle-free ‘dominates’ injectable drug delivery market appeared first on European Pharmaceutical Review.

Magenta Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results and Recent Business Highlights

-- Declared development candidate in first targeted conditioning program -- -- Phase 1 study for first-line stem cell mobilization program to begin 1H19 -- -- Presented updated clinical data for MGTA-456 cell therapy showing signs of early benefit in patients with inherited metabolic disorders (IMDs) -- -- Ended 201...

AZ's Farxiga reduces major adverse cardiovascular event risk in type 2 #diabetes, new data shows http://bit.ly/2Hvk7o2  #pharma @AstraZenecapic.twitter.com/6b1TUnxMc6

AZ's Farxiga reduces major adverse cardiovascular event risk in type 2 #diabetes, new data shows http://bit.ly/2Hvk7o2  #pharma @AstraZeneca pic.twitter.com/6b1TUnxMc6

AZ's Farxiga reduces major adverse cardiovascular event risk in type 2 diabetes, new data shows

AstraZeneca has lifted the curtain on new Phase 3 data for its sodium-glucose co-transporter 2 (SGLT2) inhibitor Farxiga (dapagliflozin), reinforcing the drug’s efficacy in reducing the relative risk of major adverse cardiovascular events (MACE) in patients with type-2 diabetes (T2D) who had a prior heart attack. Findings from a pre-specified sub-analysis indicated that the therapy reduced the r...


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks